Microglial Biology in Neuroinflammatory Disease: Pharmaco-industrial Approach to Target Validation
暂无分享,去创建一个
Thomas Möller | Paul D. Wes | Dario Doller | T. Möller | D. Doller | P. Wes
[1] T. Möller,et al. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. , 2002, Current opinion in investigational drugs.
[2] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[3] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[4] H. Waterbeemd. Improving compound quality through in vitro and in silico physicochemical profiling. , 2009 .
[5] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[6] P. Gubellini,et al. Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia , 2013, Neuropharmacology.
[7] T. Möller,et al. Microglia Biology in Health and Disease , 2006, Journal of Neuroimmune Pharmacology.
[8] Paul Smith,et al. Must try harder. , 1988, The Health service journal.
[9] Thomas Möller,et al. Neuroinflammation in Huntington’s disease , 2010, Journal of Neural Transmission.
[10] Robert Mah,et al. Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[11] N. Greig,et al. Lost in Translation: Neuropsychiatric Drug Development , 2010, Science Translational Medicine.
[12] Thierry Langer,et al. Hit finding: towards 'smarter' approaches. , 2009, Current opinion in pharmacology.
[13] T. Robbins,et al. Translational approaches to obsessive‐compulsive disorder: from animal models to clinical treatment , 2011, British journal of pharmacology.
[14] A. Chadwick,et al. Overcoming psychological barriers to good discovery decisions. , 2010, Drug Discovery Today.
[15] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[16] Daniel A Erlanson,et al. Learning from our mistakes: the 'unknown knowns' in fragment screening. , 2013, Bioorganic & medicinal chemistry letters.
[17] P. Hartig,et al. Target site occupancy: emerging generalizations from clinical and preclinical studies. , 2009, Pharmacology & therapeutics.
[18] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.
[19] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[20] Harry Jubb,et al. Protein-protein interactions as druggable targets: recent technological advances. , 2013, Current opinion in pharmacology.
[21] C. Begley,et al. Reproducibility: Six red flags for suspect work , 2013, Nature.
[22] T. Möller,et al. Microglia cell culture: a primer for the novice. , 2011, Methods in molecular biology.
[23] T. Möller,et al. Microglia in ischemic brain injury. , 2010, Future neurology.
[24] Mark E Bunnage,et al. Target validation using chemical probes. , 2013, Nature chemical biology.
[25] Edward H. Kerns,et al. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.
[26] Johan Gabrielsson,et al. Optimising in vivo pharmacology studies--Practical PKPD considerations. , 2010, Journal of pharmacological and toxicological methods.
[27] Murad Melhem,et al. Translation of Central Nervous System Occupancy from Animal Models: Application of Pharmacokinetic/Pharmacodynamic Modeling , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[28] Terrence P. Kenakin,et al. A Pharmacology Primer: Theory, Application and Methods , 2004 .
[29] Edward H. Kerns,et al. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .
[30] Asher Mullard,et al. Reliability of 'new drug target' claims called into question , 2011, Nature Reviews Drug Discovery.
[31] Lorenz M Mayr,et al. Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.
[32] Paul Morgan,et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.
[33] Jayaraman Chandrasekhar,et al. Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. , 2008, Drug discovery today.
[34] Thomas Steckler,et al. Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models , 2009, Neuropsychopharmacology.
[35] J. C. Greene,et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[37] Didier Rognan,et al. The practice of medicinal chemistry , 2015 .
[38] P. Willner,et al. The validity of animal models of depression , 2004, Psychopharmacology.
[39] Jonathan Petersen,et al. Comparison of Absorbance and Fluorescence Methods for Determining Liquid Dispensing Precision , 2005 .
[40] John P. Overington,et al. Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.
[41] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[42] R. Porsolt,et al. Behavioral despair in mice: a primary screening test for antidepressants. , 1977, Archives internationales de pharmacodynamie et de therapie.
[43] Y. Nolan,et al. Parkinson's disease in the nuclear age of neuroinflammation. , 2013, Trends in molecular medicine.
[44] L. Becerra,et al. Inflaming the Brain: CRPS a Model Disease to Understand Neuroimmune Interactions in Chronic Pain , 2013, Journal of Neuroimmune Pharmacology.
[45] R. Linker,et al. The Role of the Immune System in Huntington's Disease , 2013, Clinical & developmental immunology.
[46] Ulrik Schulze,et al. Can emerging drug classes improve R&D productivity? , 2013, Drug discovery today.
[47] H. Kettenmann,et al. Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.
[48] S. Appel,et al. Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis , 2013, Journal of Neuroimmune Pharmacology.
[49] F. Heppner,et al. Microglia as Dynamic and Essential Components of the Amyloid Hypothesis , 2013, Neuron.
[50] K. Dzirasa,et al. Increasing the validity of experimental models for depression , 2012, Annals of the New York Academy of Sciences.
[51] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.